Salarius Pharmaceuticals to Merge with Decoy Therapeutics, Forming Decoy Therapeutics
Salarius Pharmaceuticals announces a merger with Decoy Therapeutics to advance innovative peptide conjugate therapeutics for diseases and oncology.
.webp&w=1920&q=75&dpl=dpl_DvHKTkTrxtw9jHK6MpkEndZCmmr3)
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company, and Decoy Therapeutics, Inc., a preclinical-stage company developing next-generation peptide conjugate therapeutics, have signed a definitive agreement to merge. The merger will create Decoy Therapeutics, a unified entity focused on advancing innovative treatments for unmet needs in infectious diseases and oncology.
The merger integrates Decoy’s proprietary IMP3ACT platform, which leverages computational design for rapid peptide conjugate therapeutic development. This technology is particularly promising for addressing novel viral pathogens like avian H5N1 flu, as well as oncology indications in gastroenterology (GI).
The newly formed Decoy Therapeutics aims to achieve value-creating milestones in both infectious diseases and oncology, leveraging its platform and expanded pipeline to address critical gaps in treatment.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Discussion